Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) alongside an immunotherapy development platform, has entered into securities purchase and warrant inducement agreements with an existing institutional investor. The transaction is expected to generate approximately $4 million in aggregate gross proceeds, providing the company with additional capital to execute its strategic priorities. The deal underscores investor confidence in Scinai's dual business model and offers the company financial flexibility to accelerate growth initiatives.
The private placement includes 2,458,334 American Depositary Shares (ADSs), or pre-funded warrants in lieu thereof, together with warrants to purchase up to 3,687,501 additional ADSs. These securities were offered at a combined purchase price of $1.20 per ADS and accompanying warrants. In addition, under the warrant inducement agreement, the investor will immediately exercise existing warrants covering 879,194 ADSs at a reduced exercise price of $1.20 per ADS and will receive new warrants to purchase up to 1,318,791 ADSs. The newly issued Series A-1 warrants will be immediately exercisable at $1.20 per ADS and have five-year terms. The transactions are expected to close on or about Oct. 15, 2026, subject to customary conditions. A.G.P./Alliance Global Partners is serving as sole placement agent for the transactions.
Scinai intends to use the net proceeds, together with existing cash resources, to expand its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. This allocation reflects the company's commitment to strengthening its CDMO operations, which provide development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. By bolstering its CDMO capabilities, Scinai aims to capture growing demand for outsourced biopharmaceutical services while simultaneously advancing its proprietary immunology therapies licensed from the Max Planck Society and PinCell S.r.l.
The importance of this financing lies in its potential to de-risk Scinai's near-term objectives and enhance shareholder value. The participation of an existing institutional investor signals continued support for Scinai's business strategy and may improve market perception of the company's prospects. For a micro-cap biopharmaceutical firm, securing nondilutive-friendly capital through a warrant inducement can be a prudent move, as it brings in immediate cash while reducing the overhang of existing warrants. The reduced exercise price of $1.20 per ADS for the induced warrants aligns the investor's interests with those of the company, as the investor now has a greater incentive to see the share price appreciate above that level.
Scinai's CDMO segment, Scinai Biopharma Services Ltd., offers development and manufacturing services to third-party clients, generating revenue that can help offset the costs of its immunotherapy research. Expanding this platform could lead to additional contracts and recurring revenue streams, which are particularly valuable for a company with a pipeline that has not yet reached commercialization. The selective investment in the immunotherapy pipeline suggests that Scinai will continue to prioritize its most promising candidates while managing cash burn. Investors can track the latest news and updates relating to SCNI in the company's newsroom at https://ibn.fm/SCNI.
The transaction also highlights the role of specialized communications platforms in disseminating timely information to the investment community. MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content, is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. Through InvestorWire, IBN provides access to a vast network of wire solutions to reach diverse target markets. The platform also offers editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers. These services help companies like Scinai reach a wide audience of investors, influencers, and journalists. For more information, visit www.MissionIR.com.
In summary, Scinai's $4 million private placement and warrant inducement transaction provides essential funding for its CDMO expansion and immunotherapy pipeline, while demonstrating ongoing institutional support. The deal's structure, with immediate exercise of existing warrants and new five-year warrants, may reduce future financing uncertainty and align investor interests with the company's growth trajectory. As Scinai works to advance its customer programs and therapeutic candidates, the additional capital could be a catalyst for operational milestones and potential value creation.
